MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 598886 | Name: Limaprost alfadex

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Limaprost alfadex is an oral drug for the circulatory system (for confinement-related thromboangiitis ulcer, sharp pain, anaphrodisia and ischemia characteristics symptom, the improvement of subjective symptom and walking ability with postnatal lumbar spinal canal stenosis).

Chemical Structure

Limaprost alfadex
Limaprost alfadex
CAS#88852-12-4 (alfadex)

Theoretical Analysis

MedKoo Cat#: 598886

Name: Limaprost alfadex

CAS#: 88852-12-4 (alfadex)

Chemical Formula: C57H94O35

Exact Mass:

Molecular Weight: 1339.34

Elemental Analysis: C, 51.12; H, 7.07; O, 41.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
74397-12-9 (free) 88852-12-4 (alfadex)
Synonym
Prorenal; Limaprost alfadex; OP 1306 - alpha-cyclodextrin; Opalmon;
IUPAC/Chemical Name
alpha-Cyclodextrin, compd. with (2E)-7-((1R,2R,3R)-3-hydroxy-2-((1E,3S,5S)-3-hydroxy-5-methyl-1-nonenyl)-5-oxocyclopentyl)-2-heptenoic acid
InChi Key
AURWGUVCKQSRJX-AAHQNLRKSA-N
InChi Code
InChI=1S/C36H60O30.C21H34O5/c37-1-7-25-13(43)19(49)31(55-7)62-26-8(2-38)57-33(21(51)15(26)45)64-28-10(4-40)59-35(23(53)17(28)47)66-30-12(6-42)60-36(24(54)18(30)48)65-29-11(5-41)58-34(22(52)16(29)46)63-27-9(3-39)56-32(61-25)20(50)14(27)44;1-3-4-8-15(2)13-16(22)11-12-18-17(19(23)14-20(18)24)9-6-5-7-10-21(25)26/h7-54H,1-6H2;7,10-12,15-18,20,22,24H,3-6,8-9,13-14H2,1-2H3,(H,25,26)/b;10-7+,12-11+/t7-,8-,9-,10-,11-,12-,13-,14-,15+,16+,17-,18-,19-,20-,21-,22-,23-,24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-,35-,36-;15-,16+,17+,18+,20+/m10/s1
SMILES Code
OC[C@@H](O1)[C@@H]2[C@H](O)[C@@H](O)[C@H]1O[C@@H]([C@H](O)[C@H]3O)[C@@H](CO)O[C@@H]3O[C@@H]([C@H]([C@H]4O)O)[C@@H](CO)O[C@@H]4O[C@H]([C@@H](CO)O5)[C@H](O)[C@@H](O)[C@H]5O[C@H]([C@@H](CO)O6)[C@H](O)[C@@H](O)[C@H]6O[C@@H]([C@H]([C@H]7O)O)[C@@H](CO)O[C@@H]7O2.OC(/C=C/CCC[C@@H]8[C@@H](/C=C/[C@H](C[C@H](CCCC)C)O)[C@@H](CC8=O)O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,339.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Inoue Y, Sekiya N, Katayama K, Narutaki S, Yamamoto M, Iohara D, Hirayama F, Uekama K. Stabilizing effect of β-cyclodextrin on Limaprost, a PGE₁ derivative, in Limaprost alfadex tablets (Opalmon) in highly humid conditions. Chem Pharm Bull (Tokyo). 2014;62(8):786-92. Epub 2014 May 23. PubMed PMID: 24859193. 2: Onda A, Kikuchi S, Yabuki S, Otani K, Nikaido T, Watanabe K, Konno S. Limaprost alfadex and nonsteroidal anti-inflammatory drugs for sciatica due to lumbar spinal stenosis. Eur Spine J. 2013 Apr;22(4):794-801. doi: 10.1007/s00586-012-2551-1. Epub 2012 Oct 23. PubMed PMID: 23090093; PubMed Central PMCID: PMC3631040. 3: Kanchiku T, Imajo Y, Suzuki H, Yoshida Y, Taguchi T, Tominaga T, Toyoda K. Comparisons on efficacy of elcatonin and limaprost alfadex in patients with lumbar spinal stenosis and concurrent osteoporosis: a preliminary study using a crossover design. Asian Spine J. 2014 Aug;8(4):469-75. doi: 10.4184/asj.2014.8.4.469. Epub 2014 Aug 19. PubMed PMID: 25187864; PubMed Central PMCID: PMC4149990. 4: Uesawa M, Muroi K, Ozawa K. Plasmapheresis-refractory transplantation-associated thrombotic microangiopathy successfully treated with pravastatin and limaprost alfadex. Ther Apher Dial. 2013 Aug;17(4):462-3. doi: 10.1111/1744-9987.12015. Epub 2013 Feb 17. PubMed PMID: 23931890. 5: Kurokawa R, Nagayama E, Murata H, Kim P. Limaprost alfadex, a prostaglandin E1 derivative, prevents deterioration of forced exercise capability in rats with chronic compression of the spinal cord. Spine (Phila Pa 1976). 2011 May 15;36(11):865-9. doi: 10.1097/BRS.0b013e3181e878a1. PubMed PMID: 21192291. 6: Inoue A, Sawada Y, Ohmori S, Omoto D, Haruyama S, Yoshioka M, Nishio D, Nakamura M. Lichenoid Drug Eruption Caused by Limaprost Alfadex. Acta Derm Venereol. 2016 Nov 2;96(7):997-998. doi: 10.2340/00015555-2435. PubMed PMID: 27068583. 7: Nakade S, Komaba J, Ohno T, Kitagawa J, Furukawa K, Miyata Y. Bioequivalence study of two limaprost alfadex 5 microg tablets in healthy subjects: moisture-resistant tablet (dextran formulation) versus standard tablet (lactose formulation). Int J Clin Pharmacol Ther. 2008 Jan;46(1):42-7. PubMed PMID: 18218297. 8: Sugawara T, Hirano Y, Higashiyama N, Mizoi K. Limaprost alfadex improves myelopathy symptoms in patients with cervical spinal canal stenosis. Spine (Phila Pa 1976). 2009 Mar 15;34(6):551-5. doi: 10.1097/BRS.0b013e31819a84ec. PubMed PMID: 19282734. 9: Park YS, Park JH, Kim SH, Lee MH, Lee YS, Yang SC, Kang JS. Pharmacokinetic characteristics of a vasodilatory and antiplatelet agent, limaprost alfadex, in the healthy Korean volunteers. Clin Appl Thromb Hemost. 2010 Jun;16(3):326-33. doi: 10.1177/1076029609334125. Epub 2009 Oct 13. PubMed PMID: 19825922. 10: Inoue Y, Sekiya N, Yamamoto M, Iohara D, Hirayama F, Uekama K. Formation of the ternary inclusion complex of limaprost with α- and β-cyclodextrins in aqueous solution. Chem Pharm Bull (Tokyo). 2015;63(5):318-25. doi: 10.1248/cpb.c14-00733. PubMed PMID: 25948325. 11: Moribe K, Sekiya N, Fujito T, Yamamoto M, Higashi K, Yokohama C, Tozuka Y, Yamamoto K. Stabilization mechanism of limaprost in solid dosage form. Int J Pharm. 2007 Jun 29;338(1-2):1-6. Epub 2007 Feb 12. PubMed PMID: 17350191. 12: Sugiyama N, Sasayama D, Amano N. Massive epistaxis and subconjunctival hemorrhage due to combination of paroxetine and limaprost alfadex: a case report. Prim Care Companion J Clin Psychiatry. 2007;9(3):240-1. PubMed PMID: 17632667; PubMed Central PMCID: PMC1911174. 13: Nakamura M. The NMatrix, a new method of presenting statistics, displays the characteristics of medicines with similar effects used in the treatment of lumbar spinal stenosis concisely and clearly, facilitating the selection of appropriate medications. J Orthop Sci. 2015 Jul;20(4):601-8. doi: 10.1007/s00776-015-0716-6. Epub 2015 Apr 10. PubMed PMID: 25860574. 14: Gauchan P, Andoh T, Kato A, Sasaki A, Kuraishi Y. Effects of the prostaglandin E1 analog limaprost on mechanical allodynia caused by chemotherapeutic agents in mice. J Pharmacol Sci. 2009 Mar;109(3):469-72. Epub 2009 Mar 11. PubMed PMID: 19276613. 15: Sekiya N, Nishiwaki A, Nishiura A, Yamamoto M, Takeda K, Iohara D, Hirayama F, Arima H, Uekama K. Improved stability of Opalmon tablets under humid conditions IV: effect of polysaccharides and disintegrants on the stability and dissolution property of Opalmon tablets. Chem Pharm Bull (Tokyo). 2008 Jan;56(1):7-11. PubMed PMID: 18175966. 16: Zhao HP, Xiang BR. Discontinued cardiovascular drugs in 2013 and 2014. Expert Opin Investig Drugs. 2015;24(8):1083-92. doi: 10.1517/13543784.2015.1051619. PubMed PMID: 26162717. 17: Tamura T, Sakaeda T, Kadoyama K, Okuno Y. Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci. 2012;9(6):441-6. doi: 10.7150/ijms.4549. Epub 2012 Jul 25. PubMed PMID: 22859904; PubMed Central PMCID: PMC3410363. 18: Ozawa H, Abiko Y, Akimoto T. [A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs]. Yakushigaku Zasshi. 2003;38(1):93-105. Japanese. PubMed PMID: 14570069. 19: Kanai A, Osawa S, Suzuki A, Ishimaru R, Hoka S. Effectiveness of prostaglandin E1 for the treatment of patients with neuropathic pain following herpes zoster. Pain Med. 2007 Jan-Feb;8(1):36-40. PubMed PMID: 17244102. 20: Sanai T, Matsui R, Hirano T. LDL apheresis for cholesterol embolism following coronary artery bypass graft surgery--a case report. Angiology. 2006 May-Jun;57(3):379-82. PubMed PMID: 16703200.